The $7M asset sale is a small, conditional transaction that modestly boosts the cash component of the merger consideration. Monitor the merger vote and regulatory clearances; the dividend increase is a secondary effect.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $3.77entry
- T+1 · 20h ago −1.59%α +0.32% · $3.71
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics entered into an asset purchase agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third party for approximately $7.0 million in cash. The sale is contingent on the closing of Fulcrum's pending merger with Slate Medicines (or, if the merger is terminated, upon receipt of necessary approvals). Proceeds will be placed into escrow and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders in connection with the merger.
Key Financial Metrics
Key Facts
- Fulcrum and Slate entered into an asset purchase agreement on November 7, 2026 for Fulcrum's early-stage HbF assets.
- Sale price is approximately $7.0 million in cash.
- Closing is contingent on consummation of the Fulcrum-Slate merger (Merger Agreement dated August 16, 2026) or, if merger is terminated, upon receipt of necessary approvals.
- Proceeds will be funded into escrow before the merger closes and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders.
Financial Impact
$7.0 million cash sale of early-stage HbF assets; proceeds increase net cash and expected merger dividend.
Risk Factors
- Asset sale is contingent on merger closing; if merger fails, sale requires separate approvals and may not close.
- The $7M amount is small relative to typical biotech deal sizes and may not materially change the merger's economics.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-458402 |
| Document: 0001193125-26-458402-index-headers.html | 0001193125-26-458402 |
| Document: 0001193125-26-458402-index.html | 0001193125-26-458402 |
| Document: 0001193125-26-458402.txt | 0001193125-26-458402 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Viewing Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers